Back to dashboard
CommercialBilling CodesMedium impact

Medical Criteria Update for April 6, 2022

Blue Cross NC·NC · Oncology, Hematology, Rheumatology +2 more·Medical Policy
Effective date
Apr 6, 2022
We identified it
Jun 16, 2026
Days to comply

Summary

Blue Cross NC updated their medical criteria to add five new specialty drugs with associated HCPCS codes (Nexviazyme, Saphnelo, Tezspire, Enjaymo, and Leqvio) and updated the HCPCS code for Evkeeza from a temporary code to permanent code J1305. These changes provide clarity for billing these specialty medications.

Action Required

Action needed
Immediately: Billing team must update drug billing system to use permanent HCPCS code J1305 for Evkeeza instead of temporary codes. Add the five new specialty drugs (Nexviazyme, Saphnelo, Tezspire, Enjaymo, Leqvio) with their respective HCPCS codes to the billing system if administering these medications. Verify individual drug policies for specific prior authorization requirements.

Affected Billing Codes

C9085
J3490
J3590
C9086
C9399
J1305